Saso Srdjan, Logan Karl, Abdallah Yazan, Louis Louay S, Ghaem-Maghami Sadaf, Smith J Richard, Del Priore Giuseppe
Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.
J Transplant. 2012;2012:134936. doi: 10.1155/2012/134936. Epub 2011 Nov 10.
Uterine transplantation has been proposed as a possible solution to absolute uterine factor infertility untreatable by any other option. Since the first human attempt in 2000, various teams have tried to clarify which immunosuppressant would be most suitable for protecting the allogeneic uterine graft while posing a minimal risk to the fetus. Cyclosporine A (CsA) is an immunosuppressant widely used by transplant recipients. It is currently being tested as a potential immunosuppressant to be used during UTn. Its effect on the mother and fetus and its influence upon the graft during pregnancy have been of major concern. We review the role of CsA in UTn and its effect on pregnant transplant recipients and their offspring.
子宫移植已被提出作为解决绝对子宫因素不孕症的一种可能方案，而其他任何方法都无法治疗这种不孕症。自2000年首次进行人体尝试以来，各个团队都在试图弄清楚哪种免疫抑制剂最适合保护同种异体子宫移植物，同时对胎儿造成的风险最小。环孢素A（CsA）是移植受者广泛使用的一种免疫抑制剂。目前它正在作为子宫移植期间可能使用的免疫抑制剂进行测试。它对母亲和胎儿的影响以及在怀孕期间对移植物的影响一直是人们主要关注的问题。我们综述了环孢素A在子宫移植中的作用及其对怀孕的移植受者及其后代的影响。
